CRNX250516C30000
- 2.50
- 0.000.00%
Crinetics Newsroom
J.P. Morgan Maintains Crinetics(CRNX.US) With Buy Rating, Announces Target Price $53
Stifel Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $60
Crinetics Pharmaceuticals Analyst Ratings
Stifel Initiates Crinetics(CRNX.US) With Buy Rating, Announces Target Price $60
Morgan Stanley Initiates Crinetics(CRNX.US) With Buy Rating, Announces Target Price $70
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $68 to $100
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $68 to $97
TD Cowen Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)
TD Cowen Initiates Crinetics(CRNX.US) With Buy Rating
Crinetics Initiated With a Buy at TD Cowen
Crinetics Pharmaceuticals Analyst Ratings
Wolfe Research Initiates Crinetics(CRNX.US) With Hold Rating
Jefferies Upgrades Crinetics(CRNX.US) to Buy Rating, Maintains Target Price $55
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Oppenheimer Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $73
Crinetics Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $81
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $55 to $92
Crinetics Pharmaceuticals' Atumelnant Trial Data Prompts Hold Rating Amid Efficacy and Safety Concerns
Strong Buy Rating for Crinetics Pharmaceuticals Driven by Promising Atumelnant Data and Market Potential